Logotype for Dimed S.A. Distribuidora de Medicamentos

Dimed (PNVL3) Q3 2025 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Dimed S.A. Distribuidora de Medicamentos

Q3 2025 earnings summary

13 Jul, 2026

Executive summary

  • Achieved 14.3% year-over-year retail gross revenue growth in 3Q25, reaching R$1.47 billion, with record productivity and positive free cash flow for the third consecutive quarter.

  • Digital sales accounted for 26.4% of retail revenue, growing 42.4% year-over-year, with the app driving 54.1% of digital sales.

  • Private label sales grew 32.6% year-over-year, now representing 7.3% of retail sales and 37.6% share in the southern region.

  • Opened 51 new stores in the last 12 months, totaling 651 units, and maintained market leadership in the South with 22 consecutive quarters of share gains.

  • Same-store sales rose 9.1% year-over-year, with mature stores averaging R$811,000/month.

Financial highlights

  • Adjusted EBITDA reached R$79.9 million in 3Q25, up 11.3% year-over-year, with a 5.4% margin.

  • Adjusted net income was R$34.3 million (2.3% margin), the highest nominal and percentage result of 2025.

  • Free cash flow generation was R$16.0 million, with operating cash flow over R$73 million and a 6-day improvement in the cash conversion cycle.

  • Net debt/EBITDA improved to 1.0x, with the lowest leverage in the sector and average debt cost at CDI -1.3%.

  • Retail gross margin stood at 29.9%, stable or slightly improved year-over-year, despite GLP-1 pressure.

Outlook and guidance

  • Optimistic for Q4, historically the strongest quarter, and for 2026, with continued focus on digital, private label, and generics.

  • Plans to expand in the South, especially interior markets, and maintain disciplined capital allocation.

  • Expect gradual margin improvement and sustainable growth in sales and profitability.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more